Zentalis Pharmaceuticals (NASDAQ:ZNTL) Upgraded to Sell at Wall Street Zen

Key Points

• Wall Street Zen raised its rating on Zentalis Pharmaceuticals from “strong sell” to “sell.” Despite this cautious view, MarketBeat’s analyst consensus is “Moderate Buy,” with an average price target of $8.29.
• ZNTL opened at $1.70, well below its 50-day average of $2.53; shares have traded between $1.28 and $6.95 over the past year.
• The company reported a quarterly loss of $0.34 per share, narrower than analysts’ expected loss of $0.54 per share.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) was upgraded by stock analysts at Wall Street Zen from a "strong sell" rating to a "sell" rating in a research report issued on Saturday, Wall Street Zen reports.

Several other research analysts have also recently issued reports on ZNTL. Weiss Ratings reiterated a "sell (d-)" rating on shares of Zentalis Pharmaceuticals in a report on Friday, October 2nd. Leerink Partners started coverage on Zentalis Pharmaceuticals in a report on Monday, October 5th. They set an "outperform" rating and a $8.00 target price on the stock. HC Wainwright reissued a "buy" rating and set a $10.00 target price on shares of Zentalis Pharmaceuticals in a report on Monday, October 19th. Wedbush upgraded Zentalis Pharmaceuticals from a "neutral" rating to an "outperform" rating and upped their target price for the stock from $5.00 to $6.00 in a research report on Tuesday. Finally, Rodman & Renshaw initiated coverage on Zentalis Pharmaceuticals in a research note on Thursday, July 23rd. They set a "buy" rating and a $11.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $8.29.

Zentalis Pharmaceuticals Stock Up 1.2%

ZNTL stock opened at $1.70 on Friday. The company has a 50-day simple moving average of $2.53 and a 200 day simple moving average of $3.38. The company has a market capitalization of $121.84 million, a P/E ratio of -0.89 and a beta of 1.91. Zentalis Pharmaceuticals has a fifty-two week low of $1.28 and a fifty-two week high of $6.95.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last released its earnings results on Monday, November 9th. The company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.54) by $0.20. Equities analysts anticipate that Zentalis Pharmaceuticals will post -1.80 EPS for the current year.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of ZNTL. Empowered Funds LLC bought a new position in shares of Zentalis Pharmaceuticals during the 3rd quarter valued at about $211,000. 49 Wealth Management LLC acquired a new position in shares of Zentalis Pharmaceuticals in the 3rd quarter worth approximately $179,000. Russell Investments Group Ltd. raised its holdings in shares of Zentalis Pharmaceuticals by 1,834.6% in the 3rd quarter. Russell Investments Group Ltd. now owns 77,383 shares of the company's stock worth $214,000 after purchasing an additional 73,383 shares in the last quarter. Jefferies Financial Group Inc. bought a new stake in shares of Zentalis Pharmaceuticals in the 3rd quarter worth approximately $122,000. Finally, Eiger Wealth Management LLC raised its holdings in shares of Zentalis Pharmaceuticals by 33.8% in the 3rd quarter. Eiger Wealth Management LLC now owns 115,112 shares of the company's stock worth $319,000 after purchasing an additional 29,095 shares in the last quarter.

Key Zentalis Pharmaceuticals News

Investors following ZNTL have been watching these news items:

• Positive Sentiment: Wedbush upgraded Zentalis’s stock rating, another potentially supportive analyst signal. Zentalis Pharmaceuticals Stock Rating Upgraded by Wedbush
• Neutral Sentiment: Morgan Stanley maintained a Hold rating, indicating it did not see enough reason to change its stance. Morgan Stanley Remains a Hold on Zentalis Pharmaceuticals
• Negative Sentiment: HC Wainwright lowered its FY2029 and FY2030 EPS forecasts, to ($1.10) from ($1.00) and to ($0.42) from ($0.18), respectively. These later-year cuts partially offset its more favorable revisions for nearer-term years.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule medicines for cancer. Its research centers on therapies that target biological processes involved in tumor growth. The company's lead drug candidate, azenosertib (formerly known as ZN-c3), is an investigational inhibitor of WEE1, a protein involved in cell-cycle regulation. It has been studied in clinical trials for ovarian cancer and other solid tumors. Zentalis has also advanced other oncology drug candidates, including compounds targeting cancer-related proteins.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.